Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRET EDWARD BUCKLEY FRIDAY

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1346213097
CMS profile
515457
Location
DULUTH, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$56.43

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $33.07 1
Education $23.36 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Novocure Inc. $33.07 1
Gilead Sciences, Inc. $11.92 1
Deciphera Pharmaceuticals Inc. $11.44 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRET EDWARD BUCKLEY FRIDAY

NPI 1346213097 · CMS profile ID 515457

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DULUTH, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346213097?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRET EDWARD BUCKLEY FRIDAY, NPI 1346213097, CMS profile ID 515457. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346213097?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRET EDWARD BUCKLEY FRIDAY, NPI 1346213097, CMS profile ID 515457. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346213097?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRET EDWARD BUCKLEY FRIDAY, NPI 1346213097, CMS profile ID 515457, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1346213097?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $56.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Deciphera Pharmaceuticals Inc. $11.4410/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826795251 CMS
Novocure Inc. $33.0707/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 823636179 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845873083 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $56.43 3
PY2024 $74.62 2
PY2025 $30.94 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $230,390.48 14
PY2024 Principal investigator $29,134.00 10
PY2023 Principal investigator $45,776.00 9
PY2022 Principal investigator $46,676.00 14
PY2021 Principal investigator $49,852.00 18
PY2020 Principal investigator $76,793.50 25
PY2019 Principal investigator $73,190.00 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 12/03/2020 Non-covered Recipient Entity
ESSENTIA HLTH NCORP
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 740830807
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 12/03/2020 Non-covered Recipient Entity
ESSENTIA HLTH NCORP
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 740833565
Principal investigator 1 PFIZER INC. $1,750.00 12/02/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742881517
Principal investigator 1 PFIZER INC. $1,750.00 12/02/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742881927
Principal investigator 1 PFIZER INC. $500.00 11/17/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742881799
Principal investigator 1 PFIZER INC. $500.00 11/17/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742882667
Principal investigator 1 PFIZER INC. $500.00 11/17/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742882671
Principal investigator 1 PFIZER INC. $1,000.00 09/18/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742881583
Principal investigator 1 PFIZER INC. $600.00 09/18/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742881585
Principal investigator 1 PFIZER INC. $600.00 09/18/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742881589
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 09/03/2020 Non-covered Recipient Entity
ESSENTIA HLTH NCORP
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 740830797
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 09/03/2020 Non-covered Recipient Entity
ESSENTIA HLTH NCORP
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 740830805
Principal investigator 1 PFIZER INC. $500.00 06/28/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742889677
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,642.00 06/09/2020 Non-covered Recipient Entity
Essentia Health
Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents No dispute reported 06/30/2026 736740417
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 06/04/2020 Non-covered Recipient Entity
ESSENTIA HLTH NCORP
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 740830803
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 06/04/2020 Non-covered Recipient Entity
ESSENTIA HLTH NCORP
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 740833567
Principal investigator 1 PFIZER INC. $600.00 05/28/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742888307
Principal investigator 1 PFIZER INC. $600.00 05/01/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742888301
Principal investigator 1 PFIZER INC. $600.00 05/01/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742889669
Principal investigator 1 Merck Sharp & Dohme Corporation $41.50 03/13/2020 Non-covered Recipient Entity
ESSENTIA HLTH NCORP
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 740830799
Principal investigator 1 PFIZER INC. $600.00 03/11/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742889673
Principal investigator 1 Celgene Corporation $22,060.00 02/17/2020 Non-covered Recipient Entity
Essentia Health Duluth Clinic 2nd Street Building
Celgene - Connect MDS/AML No dispute reported 06/30/2026 753365835
Principal investigator 1 Celgene Corporation $31,480.00 02/11/2020 Non-covered Recipient Entity
Essentia Health Duluth Clinic 2nd Street Building
Celgene - Connect MM No dispute reported 06/30/2026 753365837
Principal investigator 1 PFIZER INC. $600.00 01/15/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742888303
Principal investigator 1 PFIZER INC. $600.00 01/15/2020 Non-covered Recipient Entity
Essentia Institute of Rural Health
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 742889417